X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49) 49
osteosarcoma (29) 29
index medicus (28) 28
oncology (26) 26
bone neoplasms - genetics (20) 20
osteosarcoma - genetics (20) 20
bone neoplasms - drug therapy (18) 18
osteosarcoma - drug therapy (18) 18
bone neoplasms - pathology (16) 16
female (16) 16
male (16) 16
osteosarcoma - pathology (16) 16
adult (15) 15
chemotherapy (13) 13
middle aged (13) 13
adolescent (12) 12
cell line, tumor (12) 12
p-glycoprotein (12) 12
cell biology (11) 11
drug resistance (10) 10
genetics & heredity (10) 10
aged (9) 9
child (9) 9
expression (9) 9
high-grade osteosarcoma (9) 9
pharmacology & pharmacy (9) 9
tumors (9) 9
antineoplastic agents - pharmacology (8) 8
apoptosis - drug effects (8) 8
cancer (8) 8
doxorubicin - pharmacology (8) 8
pharmacogenetics (8) 8
polymorphism, single nucleotide (8) 8
sarcoma (8) 8
tumor cells, cultured (8) 8
animals (7) 7
doxorubicin (7) 7
genome-wide association study (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
biochemistry & molecular biology (6) 6
bone cancer (6) 6
bone neoplasms - metabolism (6) 6
doxorubicin - administration & dosage (6) 6
drug interactions (6) 6
genetic predisposition to disease (6) 6
genotype (6) 6
in situ hybridization, fluorescence (6) 6
osteosarcoma - metabolism (6) 6
sarcoma, ewing - genetics (6) 6
toxicity (6) 6
young adult (6) 6
analysis (5) 5
article (5) 5
bone neoplasms - mortality (5) 5
cell cycle - drug effects (5) 5
cell proliferation - drug effects (5) 5
cell-lines (5) 5
cells (5) 5
chromosome aberrations (5) 5
cisplatin - administration & dosage (5) 5
dna repair (5) 5
gene expression (5) 5
health aspects (5) 5
metastasis (5) 5
methotrexate (5) 5
methotrexate resistance (5) 5
multidrug-resistance (5) 5
prognosis (5) 5
prognostic-factors (5) 5
abc transporters (4) 4
alleles (4) 4
anthracyclines (4) 4
antineoplastic agents - adverse effects (4) 4
biocompatibility (4) 4
child, preschool (4) 4
cisplatin (4) 4
comparative genomic hybridization (4) 4
disease-free survival (4) 4
dna, neoplasm - genetics (4) 4
drug resistance, neoplasm (4) 4
drug resistance, neoplasm - drug effects (4) 4
drug resistance, neoplasm - genetics (4) 4
european continental ancestry group - genetics (4) 4
gene (4) 4
gene expression regulation, neoplastic (4) 4
genetics (4) 4
immunohistochemistry (4) 4
medical and health sciences (4) 4
medicin och hälsovetenskap (4) 4
methotrexate - administration & dosage (4) 4
mice (4) 4
oligonucleotide array sequence analysis (4) 4
patient outcomes (4) 4
polymorphism, genetic (4) 4
research (4) 4
soft-tissue sarcomas (4) 4
tailored therapy (4) 4
treatment outcome (4) 4
abnormalities (3) 3
antibiotics, antineoplastic - pharmacology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 2016, Volume 11, Issue 11, p. e0166233
Cyclin-dependent kinase 2 (CDK2) has been reported to be essential for cell proliferation in several human tumours and it has been suggested as an appropriate... 
CYCLIN-DEPENDENT KINASES | APOPTOSIS | IN-VITRO | R-ROSCOVITINE | CANCER CELLS | HIGH-GRADE | MULTIDISCIPLINARY SCIENCES | EMERGING DRUGS | RESISTANCE | INHIBITOR | LINES | Cyclin-Dependent Kinase 2 - metabolism | Apoptosis - drug effects | Purines - pharmacology | Humans | Gene Silencing | Cyclin-Dependent Kinase 2 - genetics | Molecular Targeted Therapy | Drug Synergism | Cell Line, Tumor | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 2 - deficiency | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | DNA Damage | Gene Expression Regulation, Neoplastic - drug effects | Cell Cycle - drug effects | Doxorubicin - pharmacology | Osteosarcoma - pathology | Cell proliferation | Osteosarcoma | Dosage and administration | Research | Drug therapy | Phosphotransferases | Doxorubicin | Cisplatin | Drugs | Biotechnology | Laboratories | DNA damage | Oncology | Drug resistance | Drug development | Kinases | Cancer therapies | DNA repair | Cyclin-dependent kinase | Biomedical materials | Cell cycle | Roscovitine | Biocompatibility | Deoxyribonucleic acid--DNA | Damage assessment | Effectiveness | Cyclin-dependent kinases | Cell division | Tumor cell lines | Osteosarcoma cells | Cyclin-dependent kinase 2 | Bone cancer | Chemotherapy | Sensitivity | DNA microarrays | Inhibitors | Cell lines | Sensitivity enhancement | Combined treatment | Impact damage | Tumors | Apoptosis | Deoxyribonucleic acid | DNA
Journal Article
Current Cancer Drug Targets, ISSN 1568-0096, 03/2016, Volume 16, Issue 3, pp. 261 - 274
Clinical treatment response achievable with conventional chemotherapy in high-grade osteosarcoma (OS) is severely limited by the presence of intrinsic or... 
Chemotherapy | ABC transporters | Tailored treatments | Chemosensitization | Drug resistance | Osteosarcoma | STEM-CELLS | EMERGING DRUGS | chemosensitization | KINASE INHIBITORS | CELL-LINES | chemotherapy | CANCER | P-GLYCOPROTEIN | tailored treatments | ONCOLOGY | THERAPEUTIC TARGETS | HIGH-GRADE OSTEOSARCOMA | drug resistance | MULTIDRUG-RESISTANCE | PHASE-I | osteosarcoma
Journal Article
Nature Genetics, ISSN 1061-4036, 07/2013, Volume 45, Issue 7, pp. 799 - 803
Journal Article
Cellular and Molecular Life Sciences, ISSN 1420-682X, 2/2019, Volume 76, Issue 3, pp. 609 - 625
Doxorubicin is one of the most effective drugs for the first-line treatment of high-grade osteosarcoma. Several studies have demonstrated that the major cause... 
Life Sciences | Biomedicine, general | Biochemistry, general | P-glycoprotein | Life Sciences, general | Osteosarcoma | H 2 S-releasing doxorubicin | Endoplasmic reticulum-associated protein degradation | Cell Biology | Endoplasmic reticulum stress | S-releasing doxorubicin | CANCER CELLS | HYDROGEN-SULFIDE H2S | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-DEATH | CELL BIOLOGY | INDUCED CARDIOTOXICITY | INHIBITION | CYSTATHIONINE-BETA-SYNTHASE | HIGH-GRADE OSTEOSARCOMA | MULTIDRUG-RESISTANCE | STRESS | H2S-releasing doxorubicin | Osteosarcoma - drug therapy | Cell Survival - drug effects | Doxorubicin - therapeutic use | Humans | Immunoblotting | Drug Delivery Systems | Antibiotics, Antineoplastic - therapeutic use | Endoplasmic Reticulum - drug effects | Polymerase Chain Reaction | Inhibitory Concentration 50 | DNA Damage | Apoptosis | Drug Resistance, Neoplasm - drug effects | Ubiquitin | Pharmacogenetics | Anthracyclines | Proteolysis | Toxicity | Genes | Gene regulation | Three axis | CCAAT/enhancer-binding protein | Doxorubicin | Degradation | Hydrogen sulfide | Proteins | Biomedical materials | Ubiquitination | Protein folding | Biocompatibility | P-Glycoprotein | Efflux | Glycoprotein | Osteosarcoma cells | Gene expression | Bone cancer | Molecular modelling | Anthracycline | Quality control | Endoplasmic reticulum | Transporter | Index Medicus
Journal Article
Journal Article
Histopathology, ISSN 0309-0167, 09/2015, Volume 67, Issue 3, pp. 338 - 347
Journal Article
International Journal of Cancer, ISSN 0020-7136, 04/2018, Volume 142, Issue 8, pp. 1594 - 1601
Journal Article
Expert Opinion on Emerging Drugs, ISSN 1472-8214, 07/2019, Volume 24, Issue 3, pp. 153 - 171
Introduction: Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when... 
pharmacogenomics | Osteosarcoma | biomarkers | tailored therapy | drug resistance | targeted drugs | chemotherapy
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 01/2017, Volume 13, Issue 1, pp. 123 - 123
Journal Article
Investigational new drugs, ISSN 0167-6997, 2014, Volume 32, Issue 6, pp. 1167 - 1180
Polo-like kinase 1 (PLK1) has emerged as a prognostic factor in various neoplasms, but only scarce data have been reported for high-grade osteosarcoma (OS). In... 
ABCB1 | Medicine & Public Health | Polo-like kinase 1 | Osteosarcoma | Oncology | NMS-P937 | Pharmacology/Toxicology | Drug resistance | Novel therapeutic strategies | CANCER-CELLS | PLK1 | DEPLETION | POTENTIAL THERAPEUTIC TARGET | HIGH EXPRESSION | P53 | IN-VITRO | SCREEN | CBT-1(R) | ONCOLOGY | MALIGNANCIES | PHARMACOLOGY & PHARMACY | Osteosarcoma - drug therapy | RNA, Small Interfering - genetics | Apoptosis - drug effects | Humans | Gene Expression Profiling | RNA, Messenger - metabolism | Bone Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | Drug Interactions | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Antineoplastic Agents - pharmacology | Bone Neoplasms - genetics | Bone Neoplasms - drug therapy | Osteosarcoma - metabolism | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - pharmacology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Proto-Oncogene Proteins - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Osteosarcoma - genetics | Cell Cycle - drug effects | Quinazolines - pharmacology | ATP Binding Cassette Transporter, Sub-Family B - genetics | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | Physiological aspects | Drug targeting | Dosage and administration | Drug therapy | Phosphotransferases | Health aspects | Methods | Studies | Kinases | Cancer therapies | Pharmaceutical sciences | Tumors
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2016, Volume 15, Issue 11, pp. 2640 - 2652
Journal Article